Catalyst Dossier · compiled by CeliA 🧫
PALATIN TECHNOLOGIES INC (PTN)
Pharmaceutical Preparations · market cap $21M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Palatin Technologies (PTN) is a micro-cap pharmaceutical company with a $15M market cap and roughly $10.2M in cash, implying a runway of only ~2.8 months. Its lead asset, bremelanotide, is in Phase 3 for kidney disease, while three additional pipeline assets are in Phase 2 across obesity, hypertension, and ulcerative colitis — though bremelanotide's mechanism in the kidney disease indication is unspecified in available disclosures.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Bremelanotide | Phase 3 | Kidney Disease |
| PL3994 | Phase 2 | Hypertension |
| PL8177 | Phase 2 | Ulcerative Colitis |
Price & technical context
3-month
-62.2%
6-month
-53.2%
12-month
-97.1%
52-wk range
$5.45–$250.00
vs 50-day MA
-29.9%
vs 200-day MA
-53.4%
Realized vol
372.5%
Max drawdown
-99.5%
Daily closes through 2026-08-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PTN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.